Journal article
Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients
Abstract
Objective: In a recent randomised trial (CLOT [Comparison of Low molecular weight heparin versus Oral anticoagulant Therapy for long term anticoagulation in cancer patients with venous thromboembolism]), which evaluated secondary prophylaxis of venous thromboembolism (VTE) in cancer patients, dalteparin reduced the relative risk of recurrent VTEs by 52% compared with oral anticoagulation therapy (p = 0.002). A Canadian pharmacoeconomic analysis …
Authors
Dranitsaris G; Vincent M; Crowther M
Journal
PharmacoEconomics, Vol. 24, No. 6, pp. 593–607
Publisher
Springer Nature
Publication Date
June 2006
DOI
10.2165/00019053-200624060-00006
ISSN
1170-7690